All In Biotech

Drug Trial Radar · NCT02386761

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001

A Phase 1, Randomised Double-blind, Placebo-controlled STUDY of Single and Repeated Ascending doseS in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6001

Last checked: Nov 19, 2026Latest source record: Jul 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Nov 2014

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Mar 12, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A phase I randomised, double-blind, placebo-controlled study of single and repeated ascending doses in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of inhaled chf 6001.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • Single Ascending Dose (SAD)Drug

  • Multiple Ascending Dose (MAD)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 0-14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Clinical

    Nottingham, UK, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.